Kobayashi Pharmaceutical, a Japanese health products company embroiled in a red-yeast supplement scandal, is evaluating a potential ¥500 billion ($3.2 billion) buyout offer from private equity firms CVC Capital Partners and Nippon Sangyo Suishin Kiko, according to sources.
The proposed deal, which could include participation from Kobayashi’s founding family, comes as the company seeks to recover from a 2024 crisis tied to contaminated supplements. While no formal decisions have been made, the talks highlight a broader trend of Japanese firms pursuing privatization to avoid public shareholder pressures.
The Buyout Proposal and Key Players
The company’s founding family may also join the effort, though details remain confidential. Kobayashi has not commented directly on the negotiations, stating only that no decisions have been made at this time,
it said.
The proposal follows discussions between Kobayashi and its advisers, including bankers hired to assess the potential deal. If finalized, the buyout would mark a significant shift for the firm, which has faced mounting scrutiny since 2024 over its red-yeast supplements. The scandal, which involved reports of illness and suspected deaths, led to recalls and a ¥12.7 billion expense for the company.
The Scandal’s Aftermath and Market Impact
The red-yeast controversy, which began in early 2024, centered on supplements containing a substance linked to kidney damage and suspected fatalities. Kobayashi recalled affected products after detecting puberulic acid, a toxic compound. While the company has not confirmed any deaths directly tied to its supplements, health authorities noted a small number of deaths associated with suspected exposure,
according to Briefs Finance.
Market reactions have been mixed. Kobayashi’s shares, which are still about 13% below where they were before the 2024 scandal, remained volatile. The company’s market capitalization sat near ¥460 billion at Thursday’s Tokyo close. The proposed buyout could offer a path to stabilize its financial position, with potential premiums for shareholders.
Governance Pressures and Strategic Shifts
Oasis Management, Kobayashi’s largest shareholder with a 14.4% stake, has pushed for governance reforms since the scandal, including reduced influence from the founding family. The firm’s pressure has coincided with Kobayashi’s broader strategic pivot, which includes ¥30 billion in R&D investments over three years and a focus on tighter quality controls. A privatization could free the company from public market scrutiny, allowing it to prioritize long-term rebuilds over quarterly performance.
The move aligns with a growing trend of Japanese firms opting for privatization to escape activist investor demands. Recent examples include Hisamitsu Pharmaceutical and Taisho Pharmaceutical, which have also explored similar strategies. For Kobayashi, the buyout could provide the flexibility to address lingering trust issues while dealing with rising raw material costs and distribution shifts.
What Comes Next for Kobayashi?
The outcome of the buyout talks remains uncertain, with negotiations in early stages. If successful, the deal would represent a major turning point for Kobayashi, which has struggled to regain investor confidence. However, the company’s ability to address its quality control challenges and rebuild consumer trust will be critical to its long-term success.
For now, the focus remains on the proposed transaction and its implications for Kobayashi’s future. As the company faces this critical moment, stakeholders will be watching closely to see whether the buyout offers a viable solution to its ongoing challenges.